Esperion Therapeutics (ESPR) Inventory (2020 - 2026)

Esperion Therapeutics' Inventory history runs 7 years deep, the most recent figure standing at $104.2 million for Q1 2026.

• Quarterly Inventory rose 4.92% year-over-year to $104.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.2 million (up 4.92% YoY) and the FY2025 annual result came in at $105.1 million, up 11.25% from the prior year.
• Inventory was $104.2 million for Q1 2026 at Esperion Therapeutics, down from $105.1 million in the prior quarter.
• Across five years, Inventory topped out at $114.5 million in Q2 2025 and bottomed at $29.2 million in Q2 2022.
• A 5-year average of $70.3 million and a median of $73.1 million in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2022 — Inventory slipped 13.03% — and 2023, when it surged 86.42%.
• Esperion Therapeutics' Inventory stood at $35.2 million in 2022, then jumped by 86.42% to $65.6 million in 2023, then jumped by 43.99% to $94.5 million in 2024, then gained by 11.25% to $105.1 million in 2025, then fell by 0.87% to $104.2 million in 2026.
• Business Quant data shows ESPR's Inventory at $104.2 million in Q1 2026, $105.1 million in Q4 2025, and $108.5 million in Q3 2025.